Suncadia registers Phase 2/3 test of MRA HRS-1780 in resistant hypertension
The randomized, placebo-controlled trial joins Bayer's finerenone and KBP Biosciences' ocedurenone in the small mineralocorticoid-receptor-antagonist field for blood pressure control.
Executive Summary
- Shandong Suncadia Medicine has registered a Phase 2/3 trial testing its mineralocorticoid receptor antagonist HRS-1780 against placebo in patients with uncontrolled or resistant hypertension, using blood pressure reduction as the primary measure.
- The trial places HRS-1780 in a small but active mineralocorticoid receptor antagonist field, joining direct comparators most advanced in heart failure and kidney disease rather than hypertension itself.
- No mineralocorticoid receptor antagonist has yet established itself specifically for uncontrolled or resistant hypertension, so a controlled blood pressure result here would extend the mechanism's reach beyond its current cardiorenal footing.
- The trial is not yet recruiting, giving it a multi-year runway before any readout, while the sponsor's broad completion record across its wider pipeline offers no history yet specific to this mechanism or indication.
The trial
The study, filed under NCT07708441, will test HRS-1780 against placebo in participants who meet criteria for either uncontrolled or resistant hypertension, a population defined by trough seated systolic blood pressure of 140 mmHg or higher despite treatment. The trial is randomized, quadruple-masked, and structured across four arms, with an anticipated enrollment of 914 participants across sites in China. The primary endpoint is change from baseline in trough seated systolic blood pressure at Week 12, with secondary measures covering 24-hour ambulatory blood pressure monitoring, a randomized-withdrawal assessment at Week 52, and safety measures including eGFR decline and serum potassium elevation. The trial has not yet begun recruiting, with a start date of July 2026 and a primary completion date of April 2029. NCT07708441A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.NCT07708441
Mechanism and field shape
HRS-1780 blocks the mineralocorticoid receptor, the same target as Bayer's finerenone, AstraZeneca's balcinrenone, and KBP Biosciences' ocedurenone, all direct comparators by target and modality. Those three programs are furthest along in Phase 3 testing, but in heart failure and chronic kidney disease rather than hypertension: Bayer is running finerenone in heart failure measuring NT-proBNP change, AstraZeneca is testing balcinrenone in heart failure measuring cardiovascular death and hospitalization, and KBP Biosciences has advanced ocedurenone in hypertension itself. Across the broader mineralocorticoid receptor antagonist class, activity concentrates in cardiorenal disease, with 13 trials recorded across seven sponsors in the target-by-hypertension pairing and a maximum trial phase of Phase 4 reached by an approved comparator in a different indication. Bayer's finerenone (Kerendia) is approved for chronic kidney disease associated with type 2 diabetes and for heart failure with left ventricular ejection fraction of 40% or higher, not for hypertension.
Historical difficulty
Mineralocorticoid receptor antagonist trials in hypertension have carried a 25% failure rate at Phase 2, with one of four trials terminated, and two distinct sponsors have failed in this specific target-indication pairing. Field activity for the target overall has declined, with 1,885 recent trials against 19,140 older ones, a ratio the landscape data flags as a marker of a maturing rather than expanding research area. Median enrollment for comparable indication-and-phase trials runs 434 days, with a median trial duration of 412 days, benchmarks against which HRS-1780's multi-year timeline to its 2029 primary completion date will be measured once enrollment opens.
Sponsor profile
Shandong Suncadia Medicine carries a completed trial count of 31 with no terminations on record, and this is its only trial studying HRS-1780 to date. The company's broader pipeline spans 83 trials, including 32 recruiting and seven not yet recruiting, of which HRS-1780 in hypertension is one. The sponsor also has another hypertension program, HRS-7535, in Phase 3 testing through a different mechanism, indicating hypertension is a repeated area of investment for the company rather than a single-asset bet.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.